Research progress on the mechanism of low-density lipoprotein transendothelial transport

doi:10.11958/20251034

Abstract

Abstract:

The transendothelial transport of low-density lipoprotein (LDL) and its subendothelial accumulation represent a central pathogenic mechanism in atherogenesis. This process involves a variety of receptors and molecular mechanisms that work together to regulate the transport of LDL in endothelial cells and its accumulation in blood vessel wall. In addition to receptor-mediated transport mechanisms, physiological and pathological factors such as hormones, inflammatory mediators and metabolites also play an important role in it. Recent studies have further elucidated the critical regulatory roles of these factors in LDL transendothelial transport, suggesting that targeting LDL transcytosis may represent an effective strategy for the prevention of early atherosclerosis and the treatment of related vascular diseases. This review summarizes recent advances in this field and discusses their potential clinical applications.

Key words: lipoproteins, LDL, protein transport, atherosclerosis, cytokines, transendotheial transcytosis

CLC Number:

R543.5

Figures/Tables 1

References 34

[1]	KANG H. Regulation of acetylation states by nutrients in the inhibition of vascular inflammation and atherosclerosis[J]. Int J Mol Sci, 2023, 24(11):9338. doi:10.3390/ijms24119338.
[2]	LIU T, ZHAO D, QI Y. Global trends in the epidemiology and management of dyslipidemia[J]. J Clin Med, 2022, 11(21):6377. doi:10.3390/jcm11216377.
[3]	LUCHETTI F, CRINELLI R, NASONI M G, et al. LDL receptors, caveolae and cholesterol in endothelial dysfunction: oxLDLs accomplices or victims?[J]. Br J Pharmacol, 2021, 178(16):3104-3114. doi:10.1111/bph.15272.
[4]	HONG D Y, LEE D H, LEE J Y, et al. Relationship between brain metabolic disorders and cognitive impairment:LDL receptor defect[J]. Int J Mol Sci, 2022, 23(15):8384. doi:10.3390/ijms23158384.
[5]	ZHOU Y X, WEI J, DENG G, et al. Delivery of low-density lipoprotein from endocytic carriers to mitochondria supports steroidogenesis[J]. Nat Cell Biol, 2023, 25(7):937-949. doi:10.1038/s41556-023-01160-6.
[6]	HU Y N, WU M, YU H P, et al. Analysis of low-density lipoprotein receptor gene mutations in a family with familial hypercholesterolemia[J]. PLoS One, 2024, 19(10):e0310547. doi:10.1371/journal.pone.0310547.
[7]	BOLANLE I O, DE LIEDEKERKE BEAUFORT G C, WEINBERG P D. Transcytosis of LDL across arterial endothelium:mechanisms and therapeutic targets[J]. Arterioscler Thromb Vasc Biol, 2025, 45(4):468-480. doi:10.1161/ATVBAHA.124.321549.
[8]	KRAEHLING J R, CHIDLOW J H, RAJAGOPAL C, et al. Genome-wide RNAi screen reveals ALK1 mediates LDL uptake and transcytosis in endothelial cells[J]. Nat Commun, 2016, 7:13516. doi:10.1038/ncomms13516.
[9]	TAO B, KRAEHLING J R, GHAFFARI S, et al. BMP-9 and LDL crosstalk regulates ALK1 endocytosis and LDL transcytosis in endothelial cells[J]. J Biol Chem, 2020, 295(52):18179-18188. doi:10.1074/jbc.RA120.015680.
[10]	LEE S, SCHLEER H, PARK H, et al. Genetic or therapeutic neutralization of ALK1 reduces LDL transcytosis and atherosclerosis in mice[J]. Nat Cardiovasc Res, 2023, 2(5):438-448. doi:10.1038/s44161-023-00266-2.
[11]	HUANG L, CHAMBLISS K L, GAO X, et al. SR-B1 drives endothelial cell LDL transcytosis via DOCK4 to promote atherosclerosis[J]. Nature, 2019, 569(7757):565-569. doi:10.1038/s41586-019-1140-4.
[12]	FUNG K, HO T, XU Z, et al. Apolipoprotein A1 and high-density lipoprotein limit low-density lipoprotein transcytosis by binding SR-B1[J]. J Lipid Res, 2024, 65(4):100530. doi:10.1016/j.jlr.2024.100530.
[13]	TAO H, YANCEY P G, BLAKEMORE J L, et al. Macrophage SR-BI modulates autophagy via VPS34 complex and PPARα transcription of Tfeb in atherosclerosis[J]. J Clin Invest, 2021, 131(7):e94229. doi:10.1172/JCI94229.
[14]	PUDDU A, MONTECUCCO F, MAGGI D. Caveolin-1 and atherosclerosis: regulation of LDLs fate in endothelial cells[J]. Int J Mol Sci, 2023, 24(10):8869. doi:10.3390/ijms24108869.
[15]	SHU Y, JIN S. Caveolin-1 in endothelial cells:A potential therapeutic target for atherosclerosis[J]. Heliyon, 2023, 9(8):e18653. doi:10.1016/j.heliyon.2023.e18653.
[16]	ZHANG Y, JIA X, WANG Y, et al. Caveolin-1-mediated LDL transcytosis across endothelial cells in atherosclerosis[J]. Atherosclerosis, 2025, 402:119113. doi:10.1016/j.atherosclerosis.2025.119113.
[17]	WANG D X, PAN Y Q, LIU B, et al. Cav-1 promotes atherosclerosis by activating JNK-associated signaling[J]. Biochem Biophys Res Commun, 2018, 503(2):513-520. doi:10.1016/j.bbrc.2018.05.036.
[18]	ZHU L, LIAO Y, JIANG B. Role of ROS and autophagy in the pathological process of atherosclerosis[J]. J Physiol Biochem, 2024, 80(4):743-756. doi:10.1007/s13105-024-01039-6.
[19]	YERLY A, VAN DER VORST E, BAUMGARTNER I, et al. Sex-specific and hormone-related differences in vascular remodelling in atherosclerosis[J]. Eur J Clin Invest, 2023, 53(1):e13885. doi:10.1111/eci.13885.
[20]	YANG J, XU M, WANG Z, et al. Unraveling estrogen and PCSK9's roles in lipid metabolism disorders among ovariectomized mice[J]. Reprod Sci, 2025, 32(2):316-325. doi:10.1007/s43032-024-01614-8.
[21]	QIAN C, LIU J, LIU H. Targeting estrogen receptor signaling for treating heart failure[J]. Heart Fail Rev, 2024, 29(1):125-131. doi:10.1007/s10741-023-10356-9.
[22]	GHAFFARI S, NADERI NABI F, SUGIYAMA M G, et al. Estrogen inhibits LDL (low-density lipoprotein)transcytosis by human coronary artery endothelial cells via GPER (G-protein-coupled estrogen receptor) and SR-BI (scavenger receptor class b type 1)[J]. Arterioscler Thromb Vasc Biol, 2018, 38(10):2283-2294. doi:10.1161/ATVBAHA.118.310792.
[23]	XIE F, LI X, XU Y, et al. Estrogen mediates an atherosclerotic-protective action via estrogen receptor alpha/SREBP-1 signaling[J]. Front Cardiovasc Med, 2022, 9:895916. doi:10.3389/fcvm.2022.895916.
[24]	HUO X, SU B, QIN G, et al. HMGB1 promotes Ox-LDL-induced endothelial cell damage by inhibiting PI3K/Akt signaling pathway[J]. BMC Cardiovasc Disord, 2022, 22(1):555. doi:10.1186/s12872-022-03003-y.
[25]	GHAFFARI S, JANG E, NADERINABI F, et al. Endothelial HMGB1 is a critical regulator of LDL transcytosis via an SREBP2-SR-BI axis[J]. Arterioscler Thromb Vasc Biol, 2021, 41(1):200-216. doi:10.1161/ATVBAHA.120.314557.
[26]	RUBINELLI L, MANZO O L, SUNGHO J, et al. Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases[J]. Nat Commun, 2025, 16(1):1968. doi:10.1038/s41467-025-56869-9.
[27]	VELAGAPUDI S, WANG D, POTI F, et al. Sphingosine-1-phosphate receptor 3 regulates the transendothelial transport of high-density lipoproteins and low-density lipoproteins in opposite ways[J]. Cardiovasc Res, 2024, 120(5):476-489. doi:10.1093/cvr/cvad183.
[28]	JIA X, BAI X, YANG X, et al. VCAM-1-binding peptide targeted cationic liposomes containing NLRP3 siRNA to modulate LDL transcytosis as a novel therapy for experimental atherosclerosis[J]. Metabolism, 2022, 135:155274. doi:10.1016/j.metabol.2022.155274.
[29]	FRANSÉN K, PETTERSSON C, HURTIG-WENNLÖF A. CRP levels are significantly associated with CRP genotype and estrogen use in the lifestyle,biomarker and atherosclerosis (LBA) study[J]. BMC Cardiovasc Disord, 2022, 22(1):170. doi:10.1186/s12872-022-02610-z.
[30]	BIAN F, YANG X Y, XU G, et al. CRP-Induced NLRP3 Inflammasome Activation Increases LDL Transcytosis Across Endothelial Cells[J]. Front Pharmacol, 2019, 10:40. doi:10.3389/fphar.2019.00040.
[31]	BIAN F, CUI J, ZHENG T, et al. Reactive oxygen species mediate angiotensin II-induced transcytosis of low-density lipoprotein across endothelial cells[J]. Int J Mol Med, 2017, 39(3):629-635. doi:10.3892/ijmm.2017.2887.
[32]	MANSOUR A, MOUSA M, ABDELMANNAN D, et al. Microvascular and macrovascular complications of type 2 diabetes mellitus:Exome wide association analyses[J]. Front Endocrinol (Lausanne), 2023, 14:1143067. doi:10.3389/fendo.2023.1143067.
[33]	BAI X, YANG X, JIA X, et al. CAV1-CAVIN1-LC3B-mediated autophagy regulates high glucose-stimulated LDL transcytosis[J]. Autophagy, 2020, 16(6):1111-1129. doi:10.1080/15548627.2019.1659613.
[34]	SUN H, MA X, MA H, et al. High glucose levels accelerate atherosclerosis via NLRP3-IL/ MAPK/NF-κB-related inflammation pathways[J]. Biochem Biophys Res Commun, 2024, 704:149702. doi:10.1016/j.bbrc.2024.149702.